A Study of Safety Tolerability and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma

Study Overview

The purpose of this study is to see if two investigational drugs, called MEDI4736 and tremelimumab (either drug alone or in combination) are safe in treating adult subjects with liver cancer (hepatocellular carcinoma) that cannot be removed by surgery (unresectable).

Study Description

The purpose of this study is to see if two investigational drugs, called MEDI4736 and tremelimumab are safe in treating adult subjects with liver cancer that cannot be removed by surgery.

Additional Information

Participants will be compensated for their participation.


  • IRB Number: 1601354641
  • Research Study Identifier: TX5911
  • Principal Investigator: Bert O'Neil, MD

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

If you need assistance finding a study or if you have any questions, please email: ctsirro@iu.edu or call us at (317) 278-2176